Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries
Travelers’ diarrhea is the leading cause of illness among international travelers to developing countries. ETEC bacteria are the primary cause of this disease. ETEC is also a major cause of diarrheal disease among children living in endemic countries. A clinical Phase I study of a novel vaccine against diarrhea caused by ETEC has been successfully completed. All primary endpoints were achieved.